Cabozantinib in medullary thyroid carcinoma: Time to focus the spotlight on this rare disease

Journal of Clinical Oncology

Volumn 29, Issue 19, 2011, Pages 2616-2618

  Houvras, Yariv ^a   Wirth, Lori J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; MOTESANIB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; XL 184;

ANOREXIA; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; EDITORIAL; ERYTHEMA; FAMILIAL CANCER; FATIGUE; GENE MUTATION; HUMAN; HYPERTENSION; MUCOSA INFLAMMATION; MULTIPLE ENDOCRINE NEOPLASIA; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THYROID MEDULLARY CARCINOMA;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; GENOTYPE; HUMANS; MEDICAL ONCOLOGY; MUTATION; PHENOTYPE; PYRIDINES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 79960127292     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.0505     Document Type: Editorial

References (20)

1. Kurzrock R, Sherman SI, Ball DB, et al: Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666, 2011
2. Hundahl SA, Fleming ID, Fremgen AM, et al: A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648, 1998
3. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
4. Jiménez C, Hu MI, Gagel RF: Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am 37:481-496, x-xi, 2008
5. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al: Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612, 2009
6. Schilling T, Bürck J, Sinn HP, et al: Prognostic value of codon 918 (ATG 224 ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66, 2001
7. Yen TW, Shapiro SE, Gagel RF, et al: Medullary thyroid carcinoma: Results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134:890-899, 2003; discussion 899-901
8. Roman S, Lin R, Sosa JA: Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142, 2006 (Pubitemid 44665646)
9. Pelizzo MR, Boschin IM, Bernante P, et al: Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol 33:493-497, 2007 (Pubitemid 46586095)
10. Skinner MA, Moley JA, Dilley WG, et al: Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353:1105-1113, 2005 (Pubitemid 41317433)
11. Schlumberger M, Abdelmoumene N, Delisle MJ, et al: Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine: The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 71:363-365, 1995
12. Nocera M, Baudin E, Pellegriti G, et al: Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine: Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 83:715-718, 2000
13. Tuttle RM, Ball DW, Byrd D, et al: Medullary carcinoma. J Natl Compr Canc Netw 8:512-530, 2010
14. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
15. Lam ET, Ringel MD, Kloos RT, et al: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330, 2010
16. Carr LL, Mankoff DA, Goulart BH, et al: Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 16:5260-5268, 2010
17. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713, 2008
18. Gupta-Abramson V, Troxel AB, Nellore A, et al: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719, 2008
19. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010
20. Wells SA, Robinson BG, Gagel RF, et al: Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). J Clin Oncol 28:421s, 2010 (suppl; abstr 5503)